CASE PRESENTATION {#s1}
=================

The patient is a 6.5-yr-old boy who was referred for research genome sequencing because of a diagnosis of recurrent medulloblastoma. His initial presentation at 22 mo was prompted by a several-week history of loss of developmental milestones, persistent head tilt, and decreased responsiveness. Past medical history was notable for delivery by cesarean section at 28 wk for oligohydramnios and breech presentation, and severe feeding difficulties in early infancy necessitating fundoplication and gastrostomy-tube placement. Pertinent findings on exam at presentation included macrocephaly, listlessness, truncal ataxia, and episodic apnea. Magnetic resonance imaging (MRI) of the brain showed a 5.5-cm mass in the midline posterior fossa ([Fig. 1](#MCS004572TOKF1){ref-type="fig"}A), obstructive hydrocephalus, and mild tonsillar herniation. The patient underwent gross total resection of the tumor. Histopathologic analysis of the resected specimen was consistent with nodular/desmoplastic medulloblastoma. Immunohistochemical staining performed on a clinical basis and transcriptomic profiling performed on a research basis were both consistent with sonic hedgehog (SHH) subtype medulloblastoma. MRI of the spine and cerebrospinal fluid cytology demonstrated no evidence of leptomeningeal spread of disease. He was treated with induction, consolidation, and maintenance chemotherapy per study protocol (SJYC07) without radiation therapy. He remained disease-free until age 6.5 yr, when surveillance MRI showed a local recurrence in the original resection cavity ([Fig. 1](#MCS004572TOKF1){ref-type="fig"}B) without evidence of dissemination. The patient underwent gross total resection in which pathology was again consistent with nodular/desmoplastic medulloblastoma ([Fig. 1](#MCS004572TOKF1){ref-type="fig"}C,D). He was treated with craniospinal proton radiotherapy. Concurrently, he was enrolled in the Rady Children\'s Institute for Genomic Medicine (RCIGM) Biorepository Study (IRB \#160468) to facilitate genomic analysis of matched tumor and normal tissue samples. The results of that analysis are discussed here. The patient was subsequently treated with high-dose craniospinal proton radiation therapy, had a complete response, and remained without central nervous system (CNS) disease 18 mo after completion of therapy.

![Representative MRI images of the midline posterior fossa medulloblastoma at (*A*) initial diagnosis and (*B*) recurrence. (*C*) H&E stain of the recurrent tumor (200× magnification) showing densely cellular proliferation of "small blue cells" with nodules showing neural differentiation with pale fibrillary background. (*D*) Reticulin stain of recurrent tumor (200× magnification) showing reticulin deposition within internodular areas, outlining reticulin-negative nodules. (*E*--*G*) IGV data showing the de novo c.432+1G\>A pathogenic variant in *GNAS* is present on the paternally inherited allele. *GNAS* SNVs detected on analysis of proband tumor (*top*), maternal blood (*middle*), and paternal blood (*bottom*). The allele fraction of the paternally inherited SNVs in *E* and *F* (NM_080425) in the proband\'s tumor is similar to the allele fraction of the pathogenic splice variant (*G*) (NM_000516), indicating that the de novo splice variant has likely occurred on the paternal allele.](MCS004572Tok_F1){#MCS004572TOKF1}

TECHNICAL ANALYSIS AND METHODS {#s2}
==============================

Samples of blood and tumor were collected for genomic analysis. Whole-genome sequencing (WGS) was performed on DNA extracted from blood to assess for the presence of informative constitutional variants. Concurrently, WGS was performed on DNA extracted from tumor tissue at the time of recurrence to assess for functionally relevant somatic mutations. Attempts to isolate DNA from FFPE tumor blocks from the initial tumor resection failed to yield any usable product. WGS was performed as follows: PCR-free libraries of DNA fragments were constructed using the Illumina PCR-free Library Preparation kit according to manufacturer\'s recommendations. Paired-end sequencing (2 × 150 bp) was performed with Illumina chemistry on a HiSeq 4000 sequencer to a mean depth of coverage of 45× (blood) and 94× (tumor). Resulting sequences were aligned to the human genome reference (hg19) using the Burrows--Wheeler Aligner (BWA) and variants identified with the Genome Analysis Tool Kit (GATK). Somatic variants were identified using the Varscan, Vardict, and Strelka software packages. CONTRA analysis was applied to tumor sequence data to call copy-number variants (CNVs). Variants identified on analysis of tumor DNA that were absent from blood DNA were considered somatic mutations. All clinically reported single-nucleotide variants were orthogonally confirmed by Sanger sequencing, and all clinically reported CNVs were orthogonally confirmed by SNP array analysis (Illumina Infinium CytoSNP- 850K BeadChip v1.1).

VARIANT INTERPRETATION {#s3}
======================

Two potentially clinically significant single nucleotide variants were detected by germline and tumor WGS and are summarized in [Table 1](#MCS004572TOKTB1){ref-type="table"}. Results of tumor WGS CNV analysis and tumor SNP microarray are summarized in [Table 2](#MCS004572TOKTB2){ref-type="table"}. WGS performed on DNA extracted from the patient\'s blood sample detected a de novo heterozygous pathogenic c.432+1G\>A variant in *GNAS*. This variant affects the canonical splice donor site of intron 5 and thus is predicted to alter splicing and result in loss of normal protein function. This variant had been previously reported in the literature as a de novo change in an individual with a diagnosis of pseudopseudohypoparathyroidism ([@MCS004572TOKC14]). It is absent from the ExAC and gnomAD population databases and thus is presumed to be rare. A second maternally inherited heterozygous variant of uncertain clinical significance was detected in *DICER1*. This variant affects a highly conserved amino acid and is absent from the ExAC and gnomAD population databases. However, it has not been previously reported in the literature as a deleterious change and as such the clinical implications of this variant remain uncertain.

###### 

Single-nucleotide variants detected by genome sequencing of germline and tumor

  Gene       Transcript   Coordinates (hg19)   Nucleotide    Protein   Classification   Coverage (blood)   AF (blood)   Coverage (tumor)   AF (tumor)
  ---------- ------------ -------------------- ------------- --------- ---------------- ------------------ ------------ ------------------ ------------
  *DICER1*   NM_030621    Chr 14:95574409      c.2458A\>G    p.T820A   VUS              45×                42%          111×               43%
  *GNAS*     NM_000516    Chr 20:57478847      c.432+1G\>A   p.?       Pathogenic       47×                57%          121×               78%

(VUS) Variant of uncertain significance, (AF) allele fraction.

###### 

Structural variants detected by genome sequencing of tumor

  ISCN arr\[GRCh37\]                             Event              Size (bp)     Cancer-related genes
  ---------------------------------------------- ------------------ ------------- ---------------------------------------------
  1p32.1p22.3 (60,489,417_86,741,437) × 1        Loss               26,252,021    *JAK1, FUBP1, BCL10*
  1p21.2p12 (102,000,184_120,532,214) × 1        Loss               18,532,031    *RBM15, TRIM33, NRAS, FAM46C, NOTCH2*
  \(7\) × 3                                      Gain               159,138,663   Many, e.g., *CDK6*
  13q14.2q21.1 (49,392,118_55,549,433) × 1       Loss               6,157,316     
  20q11.21qter (30,137,047_63,025,520) × 2 hmz   Copy-neutral LOH   32,888,474    *ASXL1, MAFB, TOP1, SDC4, **GNAS**, SS18L1*

(LOH) Loss of heterozygosity.

Both the *GNAS* and *DICER1* variants were also detected by WGS of the tumor sample ([Table 1](#MCS004572TOKTB1){ref-type="table"}). Based on the allelic fraction of the *GNAS* variant, the estimated tumor purity of the sample was 50%. WGS and SNP microarray analysis of tumor additionally showed trisomy 7 and several copy-number variants including multiple deletions involving regions on Chromosomes 1p and 13q ([Table 2](#MCS004572TOKTB2){ref-type="table"}). Copy-neutral loss of heterozygosity of Chromosome 20q11.21qter encompassing *GNAS* ([Table 2](#MCS004572TOKTB2){ref-type="table"}) was also detected, consistent with biallelic loss of *GNAS* in the tumor specimen. No focal amplifications of known oncogenes or deletions of known tumor-suppressor genes were present.

SUMMARY {#s4}
=======

*GNAS* resides in a complex imprinted locus from which multiple transcripts are generated, the best characterized of which encodes Gsα (MIM: 139320) ([@MCS004572TOKC1]). Gsα is the alpha subunit of the stimulatory guanine nucleotide-binding protein, a key mediator of the cAMP signal transduction pathway ([@MCS004572TOKC6]). Biallelic expression of GNAS occurs in most tissues (Haldeman-Englert et al. 2017). However, predominant expression of the maternal allele has been demonstrated in certain tissues (e.g., thyroid epithelial cells) ([@MCS004572TOKC2]; [@MCS004572TOKC1]) and likely explains the parent-of-origin specificity of phenotypes resulting from mutations in *GNAS*. Inactivating variants affecting the maternal *GNAS* allele cause pseudohypoparathyroidism, which is characterized by multihormone resistance with an Albright hereditary osteodystrophy (AHO) phenotype (short stature, round face, subcutaneous ossifications, brachydactyly, and intrauterine growth restriction) ([@MCS004572TOKC2]). Inactivating mutations on the paternal *GNAS* allele cause pseudopseudohypoparathyroidism, which presents as AHO without endocrine dysfunction ([@MCS004572TOKC6]). Paternal *GNAS* mutations have also been implicated in additional disorders including progressive osseous heteroplasia and osteoma cutis (Haldeman-Englert et al. 2017).

The detection of a pathogenic loss-of-function variant in *GNAS* on analysis of this patient\'s blood ([Table 1](#MCS004572TOKTB1){ref-type="table"}) is consistent with a diagnosis of a constitutional *GNAS*-associated disorder. However, because the mutation occurred as a de novo change, the parent of origin of the mutated allele could not be determined on the basis of the germline sequence data alone. In addition, there were no informative single-nucleotide polymorphisms (SNPs) in close proximity to the de novo event that could be used to phase the pathogenic mutation. However, analysis of the tumor sample was informative and permitted phasing of the de novo variant to the paternal allele. WGS of the tumor showed the c.432+1G\>A variant in *GNAS* at an allele fraction of 78%. This finding, in conjunction with copy-neutral loss of heterozygosity involving 20q11.21qter encompassing *GNAS*, indicated that the normal *GNAS* allele had likely been lost in part or all of the tumor specimen. Additional remote SNPs in the *GNAS* gene were analyzed and overrepresentation of the paternal allele to a degree consistent with the allele fraction of the pathogenic splice variant was evident ([Fig. 1](#MCS004572TOKF1){ref-type="fig"}E--G), suggesting that somatic loss of the maternal *GNAS* allele and duplication of the paternal *GNAS* allele had occurred in the tumor. Thus, the c.432+1G\>A variant could be phased to the paternal allele, indicating that this patient is at risk of developing the pseudopseudohypoparathyroidism, progressive osseous heteroplasia, and/or osteoma cutis phenotypes.

The pathogenic splice variant in *GNAS* was also observed in the patient\'s medulloblastoma sample. Together with copy-neutral loss of heterozygosity encompassing the *GNAS* gene, this finding is consistent with presumed loss of normal *GNAS* expression in tumor tissue. Much is known about the molecular drivers of pediatric medulloblastoma, which have been divided into four major subgroups on the basis of transcriptomic profiling: WNT, SHH, Group 3, and Group 4 ([@MCS004572TOKC13]). The WNT and SHH subtypes are named for key signaling pathways implicated in medulloblastoma tumorigenesis. Less is known about the biological underpinnings of the latter two groups, which consequently have generic names ([@MCS004572TOKC13]). Histopathologic analysis of the tumor in this patient was consistent with desmoplastic/nodular medulloblastoma, a subgroup typically associated with SHH type tumors ([@MCS004572TOKC8]). Previous studies of medulloblastoma genomes have shown that the SHH subgroup is characterized by more regions of chromosome gain and/or loss relative to WNT medulloblastomas ([@MCS004572TOKC8]). In addition, driver mutations in a specific set of genes involved in SHH signaling (e.g., *PTCH1*) are commonly found as somatic events ([@MCS004572TOKC8]).

Germline mutations in *PTCH1* and *SUFU*, both negative regulators of the SHH pathway ([@MCS004572TOKC8]), have been linked with a predisposition to medulloblastoma development ([@MCS004572TOKC12]). Gsα, which is encoded by *GNAS*, promotes production of cAMP ([@MCS004572TOKC6]), which in turn represses SHH signaling through activation of cAMP-dependent protein kinase A ([@MCS004572TOKC5]; [@MCS004572TOKC3]). Although *GNAS* modulates SHH signaling in this way ([@MCS004572TOKC11]), inactivating variants in *GNAS* have not been tightly correlated with an increased risk of medulloblastoma or other malignant tumor formation ([@MCS004572TOKC7]). A recent report, however, describes a child with osteoma cutis and medulloblastoma who was found on biopsy of multiple affected tissues to have a homozygous nonsense variant in *GNAS* ([@MCS004572TOKC4]). The patient died from complications of surgery before a blood sample could be obtained for germline variant analysis, but it is reasonable to assume the patient was at least heterozygous for the inactivating *GNAS* variant. Furthermore, in a study of two independent cohorts of patients with SHH-driven medulloblastomas, reduced GNAS expression levels were closely correlated with unfavorable survival outcomes ([@MCS004572TOKC3]), suggesting a role for *GNAS* in medulloblastoma formation and/or progression.

In mice, loss of *Gnas* in neural stem/progenitor cells causes tumors that recapitulate the location and histologic features of human SHH-driven medulloblastomas ([@MCS004572TOKC3]). In tumor cells derived from mice with loss of *Gnas*, a significant decrease in intracellular cAMP levels was noted. This would be expected to reduce PKA-mediated repression of the Shh pathway, thereby contributing to hyperactivation of Shh signaling and tumor formation. Intriguingly, treatment of affected mice with rolipram, a phosphodiesterase type 4 inhibitor that blocks cAMP breakdown, led to reduced tumor volumes, decreased tumor cell proliferation, and significant improvements in life expectancy in treated relative to untreated mice ([@MCS004572TOKC3]). Although the clinical application of rolipram specifically is limited by its propensity to cause gastrointestinal toxicity ([@MCS004572TOKC10]), these data underscore the potential utility of cAMP agonists for the treatment of *GNAS*-inactivated SHH-driven medulloblastomas ([@MCS004572TOKC3]).

The pathogenic splice variant in *GNAS* detected in this patient was found as a constitutional mutation, whereas the copy-neutral LOH was restricted to the tumor, indicating the latter event occurred as a somatic change. In contrast to the predicted loss-of-function effect of the variants identified in this patient, putative gain-of-function variants in *GNAS* are among the most commonly detected somatic mutations in cancer. Predominantly missense variants in *GNAS* have been detected as somatic events in pituitary tumors, colorectal cancer, pancreatic cancer, and other neoplasms ([@MCS004572TOKC9]). Thus, *GNAS* may play a dual role in cancer development, acting either as a tumor suppressor or an oncogenic driver in a mutation- and possibly tumor-dependent fashion.

In summary, we describe a patient with recurrent nodular/desmoplastic medulloblastoma who was found on WGS to have a de novo pathogenic germline variant in *GNAS*. To our knowledge, this is the second report of medulloblastoma occurring in a patient with a constitutional *GNAS* variant but the first comprehensive genetic analysis incorporating germline and tumor WGS with single-nucleotide and structural variant detection. Together with a compelling mouse model ([@MCS004572TOKC3]), this report adds to the evidence implicating *GNAS* as a tumor-suppressor gene in SHH-driven medulloblastoma. With studies in mice showing the potential utility of cAMP-augmenting agents in *GNAS*-inactivated tumors, an investigation of the efficacy of such drugs in patients, particularly those with recurrent or refractory disease, is warranted.

ADDITIONAL INFORMATION {#s5}
======================

Database Deposition and Access {#s5a}
------------------------------

The reported variant in *GNAS* has been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession number SCV000623565.1. The reported variant in *DICER1* has been submitted to ClinVar and can be found under accession number SCV000987202. Raw sequencing data was submitted to dbGaP (<https://www.ncbi.nlm.nih.gov/gap/>), accession numbers pending.
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